Health
Pilot Study Finds 30-Day Molecular Improvement in Prostate Health Following Intraprostatic Ozone Therapy, Tracked by the EpiSwitch® PSE Blood Test
Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, quantified by the EpiSwitch® Prostate Cancer Detection (PSE) blood test. In this 10-patient cohort (ages 54–76), mean PSE probability scores decreased from 0.56 (±0.27) at baseline to 0.39 (±0.31) post-therapy—a relative reduction of approximately 31% (paired t-test, p=0.045; Cohen's d=0.69). Eight
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"BOCA RATON, Fla., Jan. 22, 2026 /PRNewswire/ -- Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, quantified by the EpiSwitch® Prostate Cancer Detection (PSE) blood test. In this 10-patient cohort (ages 54–76), mean PSE probability scores decreased from 0.56 (±0.27) at baseline to 0.39 (±0.31) post-therapy—a relative reduction of approximately 31% (paired t-test, p=0.045; Cohen's d=0.69). Eight of ten patients (80%) showed individual decreases; the mean PSA fell by ~20% after normalization for a single age outlier.","length":674,"tagName":"p"},{"type":"image","alt":"Doctors Studio logo","displaySize":"","headline":null,"caption":"Doctors Studio logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":147,"url":"https://media.zenfs.com/en/prnewswire.com/d4f068dbf0df9c32262eaee324a29e92"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y4dQS9z1OCrkgQgbnKViZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d4f068dbf0df9c32262eaee324a29e92","width":400,"height":147}},"href":"https://mma.prnewswire.com/media/2864801/Forum_Health_Doctors_Studio_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The EpiSwitch® PSE test is a validated, 94% accurate, blood-based assay that assesses 3D genomic conformations linked to clinically significant prostate cancer. The pilot used paired pre- and post-treatment PSE and PSA measures and included linear discriminant analysis, which demonstrated distinct clustering of pre- versus post-therapy molecular profiles.","length":357,"tagName":"p"},{"type":"text","content":""Men deserve better, faster feedback on whether an intervention is moving their biology in the right direction," said Lisbeth Roy, DO, Founder & CEO of Doctors Studio and co-author of the paper. "These early results suggest that precision molecular monitoring can help us personalize care pathways while we investigate promising adjunctive therapies. Our next step is a larger, multi-center evaluation with longer follow-up."","length":449,"tagName":"p"},{"type":"text","content":"Intraprostatic ozone was administered transperineally (20 μg/mL gamma ozone; 40 mL tot...